NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today announced the release of a Flash Report on SBC Medical Group Holdings, Inc. (NASDAQ:SBC), reiterating its Buy-Extended rating and

<p><strong id="dateline">NEW YORK CITY, NY / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 22, 2026 / </strong>Emerging Growth Research today announced the release of a Flash Report on SBC Medical Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/SBC">SBC</a>), reiterating its Buy-Extended rating and maintaining its 12-month price target of $9.00, representing potential upside from the Company's recent share price of $3.65 as of April 21, 2026.</p><p>The Flash Report provides an update following recent share price volatility tied to a secondary share transaction, while reaffirming the Company's long-term growth outlook and underlying fundamentals.</p><p><strong>Key Highlights from the Flash Report:</strong></p><ul><li><p>Secondary Share Transaction Misinterpreted by Market: SBC recently completed a secondary share issuance reflecting approximately a 3% reduction in the founder's ownership stake. Importantly, the transaction did not result in shareholder dilution, though shares declined following the offering due to the discounted pricing.</p></li><li><p>Founder Alignment Remains Strong: Despite the transaction, the founder/CEO continues to hold a significant majority stake in the Company, reinforcing long-term alignment with shareholders.</p></li><li><p>Improved Share Liquidity: The increase in public float-potentially up to 20%-is expected to enhance trading liquidity and may support broader institutional participation.</p></li><li><p>Potential Index Inclusion Catalyst: Increased float-adjusted market capitalization could improve SBC's eligibility for inclusion in the Russell Index.</p></li><li><p>Growth Recovery Expected in 2026: Following pricing-related revenue pressure in 2025, management continues to target a return to revenue growth during 2026.</p></li><li><p>Strategic Expansion Initiatives: SBC is pursuing international M&A opportunities and new initiatives in AI-driven operations and longevity-focused services.</p></li><li><p>Attractive Valuation: The recent share price pullback has created a disconnect between valuation and fundamentals, supported by a strong net cash position.</p></li></ul><p><strong>For a copy of the full Flash Report, please visit:</strong><br/><a rel="nofollow" href="https://pr.report/kwn1">https://emerginggrowth.com/wp-content/uploads/2026/04/SBC_Flash-Report_4.22.26.pdf</a></p><p>Or</p><p><a rel="nofollow" href="https://pr.report/kwn2">https://www.EmergingGrowth.com/profile/sbc/</a> (on the right side of the page as you scroll down)</p><p><strong>About SBC Medical Group</strong><br/>SBC Medical Group Holdings, Inc. provides management services to cosmetic treatment centers through a franchise model, operating across Japan, Southeast Asia, and the United States.</p><p><strong>About Emerging Growth Research</strong><br/>Emerging Growth Research is an independent equity research firm providing institutional-quality analysis on emerging growth companies.</p><p><strong>Contact:</strong><br/>Emerging Growth Research<br/><a rel="nofollow" href="mailto:Research@EmergingGrowth.com">Research@EmergingGrowth.com</a><br/><a rel="nofollow" href="https://pr.report/kwn3">www.EmergingGrowth.com</a></p><p><strong>Forward-Looking Statements</strong><br/>This press release contains forward-looking statements concerning business operations, financial performance, and future expectations of SBC Medical Group Holdings, Inc. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.</p><a href="https://app.accessnewswire.com/imagelibrary/68d772e8-5d39-42fa-8613-3533e106b446/egr-logo-for-accesswire.png" rel="nofollow"><img src="https://app.accessnewswire.com/imagelibrary/68d772e8-5d39-42fa-8613-3533e106b446/1160086/egr-logo-for-accesswire.png" style="width:605px;text-align:center;margin:0.9em auto;"></a><div> </div><div> </div><div> </div><div> </div><div> </div><p><strong>SOURCE:</strong> SBC Medical Group Holdings Incorporated</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/emerging-growth-research-releases-flash-report-on-sbc-medical-group-r-1160086'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1160086" width="0" height="0"/>

Emerging Growth Research Releases Flash Report on SBC Medical Group; Reiterates Buy-Extended Rating and $9.00 Price Target

Emerging Growth Research Affirms Buy Rating for SBC Medical Group Holdings

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today announced the release of a Flash Report on SBC Medical Group Holdings, Inc. (NASDAQ:SBC), reiterating its Buy-Extended rating and</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Emerging Growth Research has reiterated its Buy rating for SBC Medical Group Holdings, projecting a 12-month target price of $9. This reflects confidence in SBC&#039;s recovery strategy and continued founder alignment, potentially improving liquidity and institutional interest amidst recent share price volatility.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Emerging Growth Research maintains SBC&#039;s Buy-Extended rating with a $9 price target.</li><li>SBC&#039;s recent secondary share offering did not dilute shareholder value.</li><li>Founder&#039;s significant stake enhances alignment with shareholders.</li><li>Improved liquidity could attract institutional investors and index inclusion.</li><li>SBC aims for revenue growth recovery in 2026 following previous pressures.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Russell Index (RUT)</strong>: Inclusion could enhance SBC&#039;s visibility and trading volume.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This analysis fits under Corporate Developments, indicating strategic changes and growth objectives that could impact SBC&#039;s financial trajectory substantially.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>SBC&#039;s secondary share issuance misinterpreted, leading to recent price decline.</li><li>Increased float may open doors for institutional investments in SBC.</li><li>Potential inclusion in the Russell Index could elevate SBC&#039;s market presence.</li><li>Management&#039;s revenue growth targets for 2026 could attract bullish sentiment.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>SBC price on April 21, 2026, was $3.65.</li><li>Emerging Growth Research&#039;s 12-month price target for SBC is $9.00.</li><li>Recent secondary share issuance reduced founder&#039;s ownership by ~3%.</li><li>Public float may increase by up to 20%.</li><li>SBC aims for revenue growth recovery in 2026 after 2025 pressures.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors should consider a buy on SBC for mid-term growth, targeting $9 by 2027.</p>
  </section>
</section>


<p><strong id="dateline">NEW YORK CITY, NY / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 22, 2026 / </strong>Emerging Growth Research today announced the release of a Flash Report on SBC Medical Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/SBC">SBC</a>), reiterating its Buy-Extended rating and maintaining its 12-month price target of $9.00, representing potential upside from the Company's recent share price of $3.65 as of April 21, 2026.</p><p>The Flash Report provides an update following recent share price volatility tied to a secondary share transaction, while reaffirming the Company's long-term growth outlook and underlying fundamentals.</p><p><strong>Key Highlights from the Flash Report:</strong></p><ul><li><p>Secondary Share Transaction Misinterpreted by Market: SBC recently completed a secondary share issuance reflecting approximately a 3% reduction in the founder's ownership stake. Importantly, the transaction did not result in shareholder dilution, though shares declined following the offering due to the discounted pricing.</p></li><li><p>Founder Alignment Remains Strong: Despite the transaction, the founder/CEO continues to hold a significant majority stake in the Company, reinforcing long-term alignment with shareholders.</p></li><li><p>Improved Share Liquidity: The increase in public float-potentially up to 20%-is expected to enhance trading liquidity and may support broader institutional participation.</p></li><li><p>Potential Index Inclusion Catalyst: Increased float-adjusted market capitalization could improve SBC's eligibility for inclusion in the Russell Index.</p></li><li><p>Growth Recovery Expected in 2026: Following pricing-related revenue pressure in 2025, management continues to target a return to revenue growth during 2026.</p></li><li><p>Strategic Expansion Initiatives: SBC is pursuing international M&A opportunities and new initiatives in AI-driven operations and longevity-focused services.</p></li><li><p>Attractive Valuation: The recent share price pullback has created a disconnect between valuation and fundamentals, supported by a strong net cash position.</p></li></ul><p><strong>For a copy of the full Flash Report, please visit:</strong><br/><a rel="nofollow" href="https://pr.report/kwn1">https://emerginggrowth.com/wp-content/uploads/2026/04/SBC_Flash-Report_4.22.26.pdf</a></p><p>Or</p><p><a rel="nofollow" href="https://pr.report/kwn2">https://www.EmergingGrowth.com/profile/sbc/</a> (on the right side of the page as you scroll down)</p><p><strong>About SBC Medical Group</strong><br/>SBC Medical Group Holdings, Inc. provides management services to cosmetic treatment centers through a franchise model, operating across Japan, Southeast Asia, and the United States.</p><p><strong>About Emerging Growth Research</strong><br/>Emerging Growth Research is an independent equity research firm providing institutional-quality analysis on emerging growth companies.</p><p><strong>Contact:</strong><br/>Emerging Growth Research<br/><a rel="nofollow" href="mailto:Research@EmergingGrowth.com">Research@EmergingGrowth.com</a><br/><a rel="nofollow" href="https://pr.report/kwn3">www.EmergingGrowth.com</a></p><p><strong>Forward-Looking Statements</strong><br/>This press release contains forward-looking statements concerning business operations, financial performance, and future expectations of SBC Medical Group Holdings, Inc. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.</p><a href="https://app.accessnewswire.com/imagelibrary/68d772e8-5d39-42fa-8613-3533e106b446/egr-logo-for-accesswire.png" rel="nofollow"><img src="https://app.accessnewswire.com/imagelibrary/68d772e8-5d39-42fa-8613-3533e106b446/1160086/egr-logo-for-accesswire.png" style="width:605px;text-align:center;margin:0.9em auto;"></a><div> </div><div> </div><div> </div><div> </div><div> </div><p><strong>SOURCE:</strong> SBC Medical Group Holdings Incorporated</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/emerging-growth-research-releases-flash-report-on-sbc-medical-group-r-1160086'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1160086" width="0" height="0"/>

Emerging Growth Research has reiterated its Buy rating for SBC Medical Group Holdings, projecting a 12-month target price of $9. This reflects confidence in SBC's recovery strategy and continued founder alignment, potentially improving liquidity and institutional interest amidst recent share price volatility.

Emerging Growth Research Releases Flash Report on SBC Medical Group; Reiterates Buy-Extended Rating and $9.00 Price Target

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News